NCT00207077View on ClinicalTrials.gov

Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Neoplasms
Interventions
DRUG

Cetuximab + Erlotinib

IV solution + tablet, IV+ oral, ERB 100 mg/m2, 200 mg/m2, 250 mg/m2 IV + Erl 150 mg tablet, ERB weekly/ Erl once daily, Until disease progression.

Trial Locations (1)

19718

Christiana Care Health Services, Inc., Newark

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00207077 - Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter